PH
ORCID – ResearcherID
(+33)
Liste des publications :
Schleiss, C., Carapito, R., Fornecker, L.-M., Muller, L., Paul, N., Tahar, O., Pichot, A., Tavian, M., Nicolae, A., Miguet, L., Mauvieux, L., Herbrecht, R., Cianferani, S., Freund, J.-N., Carapito, C., Maumy-Bertrand, M., Bahram, S., Bertrand, F., & Vallat, L. (2021). Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia. Leukemia, 35(5), 1463–1474. https://doi.org/10.1038/s41375-021-01221-5
Michallet, A.-S., Letestu, R., Le Garff-Tavernier, M., Aanei, C. M., Ticchioni, M., Dilhuydy, M.-S., Subtil, F., Rouille, V., Mahe, B., Laribi, K., Villemagne, B., Salles, G. A., Tournilhac, O., Delmer, A. J., Portois, C., Pegourie, B., Leblond, V., Tomowiak, C., De Guibert, S., … Feugier, P. (2020). A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood. https://doi.org/10.1182/blood.2020008164
Quinquenel, A., Aurran-Schleinitz, T., Clavert, A., Cymbalista, F., Dartigeas, C., Davi, F., de Guibert, S., Delmer, A., Dilhuydy, M.-S., Feugier, P., Fornecker, L.-M., Ghez, D., Guieze, R., Laribi, K., Leblond, V., Leprêtre, S., Letestu, R., Lévy, V., Nguyen-Khac, F., … Troussard, X. (2020). Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). HemaSphere, 4(5), e473. https://doi.org/10.1097/HS9.0000000000000473
Largeaud, L., Cornillet-Lefebvre, P., Hamel, J.-F., Dumas, P.-Y., Prade, N., Dufrechou, S., Plenecassagnes, J., Luquet, I., Blanchet, O., Banos, A., Béné, M. C., Bernard, M., Bertoli, S., Bonmati, C., Fornecker, L. M., Guièze, R., Haddaoui, L., Hunault, M., Ianotto, J. C., … French Innovative Leukemia Organization (FILO). (2020). Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia. https://doi.org/10.1038/s41375-020-01031-1
Debureaux, P.-E., Febvre de Nailly, D. L., Tavernier, E., Bedoui, M., Kuhnowski, F., Tamburini, J., Fornecker, L.-M., Camus, V., Sibon, D., Moles, M.-P., Glaisner, S., Richardet, J. P., Mule, S., Calderaro, J., Azoulay, D., Fadlallah, J., Haioun, C., & Dupuis, J. (2020). Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-020-0796-6
Houillier, C., Soussain, C., Ghesquières, H., Soubeyran, P., Chinot, O., Taillandier, L., Lamy, T., Choquet, S., Ahle, G., Damaj, G., Agapé, P., Moluçon-Chabrot, C., Amiel, A., Delwail, V., Fabbro, M., Jardin, F., Chauchet, A., Moles-Moreau, M.-P., Morschhauser, F., … Gyan, E. (2020). Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. https://doi.org/10.1212/WNL.0000000000008900
Bories, P., Prade, N., Lagarde, S., Cabarrou, B., Largeaud, L., Plenecassagnes, J., Luquet, I., De Mas, V., Filleron, T., Cassou, M., Sarry, A., Fornecker, L.-M., Simand, C., Bertoli, S., Recher, C., & Delabesse, E. (2020). Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. PloS One, 15(10), e0238795. https://doi.org/10.1371/journal.pone.0238795
Michallet, A.-S., Dilhuydy, M.-S., Subtil, F., Rouille, V., Mahe, B., Laribi, K., Villemagne, B., Salles, G., Tournilhac, O., Delmer, A., Portois, C., Pegourie, B., Leblond, V., Tomowiak, C., de Guibert, S., Orsini, F., Banos, A., Carassou, P., Cartron, G., … Feugier, P. (2019). Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. The Lancet. Haematology, 6(9), e470–e479. https://doi.org/10.1016/S2352-3026(19)30113-9
Quinquenel, A., Fornecker, L.-M., Letestu, R., Ysebaert, L., Fleury, C., Lazarian, G., Dilhuydy, M.-S., Nollet, D., Guieze, R., Feugier, P., Roos-Weil, D., Willems, L., Michallet, A.-S., Delmer, A., Hormigos, K., Levy, V., Cymbalista, F., Baran-Marszak, F., & French Innovative Leukemia Organization (FILO) CLL Group. (2019). Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood, 134(7), 641–644. https://doi.org/10.1182/blood.2019000854
Tauty, A., Noblet, V., Paillard, C., Fornecker, L.-M., Namer, I. J., & Bund, C. (2019). Evaluation of the effects of chemotherapy on brain glucose metabolism in children with Hodgkin’s lymphoma. Annals of Nuclear Medicine, 33(8), 564–569. https://doi.org/10.1007/s12149-019-01363-8
Casasnovas, R.-O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., Berriolo-Riedinger, A., Fornecker, L.-M., André, M., & Meignan, M. (2019). PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors’ reply. The Lancet. Oncology, 20(4), e190. https://doi.org/10.1016/S1470-2045(19)30156-1
Casasnovas, R.-O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., Dupuis, J., Gac, A.-C., Gastinne, T., Joly, B., Bouabdallah, K., Nicolas-Virelizier, E., Feugier, P., Morschhauser, F., Delarue, R., Farhat, H., Quittet, P., Berriolo-Riedinger, A., Tempescul, A., … Meignan, M. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology, 20(2), 202–215. https://doi.org/10.1016/S1470-2045(18)30784-8
Contejean, A., Resche-Rigon, M., Tamburini, J., Alcantara, M., Jardin, F., Lengliné, E., Adès, L., Bouscary, D., Marçais, A., Lebon, D., Chabrot, C., Terriou, L., Barraco, F., Banos, A., Bussot, L., Cahn, J.-Y., Hirsch, P., Maillard, N., Simon, L., … de Fontbrune, F. S. (2019). Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 104(2), 256–262. https://doi.org/10.3324/haematol.2018.198440
Fornecker, L.-M., Muller, L., Bertrand, F., Paul, N., Pichot, A., Herbrecht, R., Chenard, M.-P., Mauvieux, L., Vallat, L., Bahram, S., Cianférani, S., Carapito, R., & Carapito, C. (2019). Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Scientific Reports, 9(1), 895. https://doi.org/10.1038/s41598-018-37273-4
Schleiss, C., Ilias, W., Tahar, O., Güler, Y., Miguet, L., Mayeur-Rousse, C., Mauvieux, L., Fornecker, L.-M., Toussaint, E., Herbrecht, R., Bertrand, F., Maumy-Bertrand, M., Martin, T., Fournel, S., Georgel, P., Bahram, S., & Vallat, L. (2019). BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Scientific Reports, 9(1), 701. https://doi.org/10.1038/s41598-018-36853-8
Lescuyer, S., Ledoux, M.-P., Gravier, S., Natarajan-Amé, S., Duval, C., Maloisel, F., Mauvieux, L., Toussaint, E., Fornecker, L.-M., & Herbrecht, R. (2019). Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 80, 134–136. https://doi.org/10.1016/j.ijid.2019.01.002
Gressin, R., Daguindau, N., Tempescul, A., Moreau, A., Carras, S., Tchernonog, E., Schmitt, A., Houot, R., Dartigeas, C., Pignon, J. M., Corm, S., Banos, A., Mounier, C., Dupuis, J., Macro, M., Fleury, J., Jardin, F., Sarkozy, C., Damaj, G., … Lymphoma Study Association. (2019). A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica, 104(1), 138–146. https://doi.org/10.3324/haematol.2018.191429
Pigneux, A., Béné, M. C., Salmi, L.-R., Dumas, P.-Y., Delaunay, J., Bonmati, C., Guièze, R., Luquet, I., Cornillet-Lefebvre, P., Delabesse, E., Ianotto, J.-C., Ojeda-Uribe, M., Hunault, M., Banos, A., Fornecker, L. M., Bernard, M., Jourdan, E., Vey, N., Zerazhi, H., … French Innovative Leukemia Organization. (2018). Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36(32), 3203–3210. https://doi.org/10.1200/JCO.2018.78.7366
Meyer, A., Fornecker, L.-M., Guffroy, A., Korganow, A.-S., & Martin, M. (2018). [Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review]. La Revue De Medecine Interne, 39(11), 882–885. https://doi.org/10.1016/j.revmed.2018.03.009
Chantepie, S. P., Garciaz, S., Tchernonog, E., Peyrade, F., Larcher, M.-V., Diouf, M., Fornecker, L.-M., Houot, R., Gastinne, T., Soussain, C., Malak, S., Lemal, R., Delette, C., Ibrahim, A., Gac, A.-C., Reboursière, E., Vilque, J.-P., Bekadja, M.-A., Casasnovas, R.-O., … Damaj, G. (2018). Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. American Journal of Hematology, 93(6), 729–735. https://doi.org/10.1002/ajh.25077
Deau, B., Amorim, S., Perrot, A., Quittet, P., Cornillon, J., Chaoui, D., Marolleau, J. P., Oberic, L., Le Du, K., Fornecker, L.-M., Tournilhac, O., Veillard, A. S., Chaillol, I., Robin, M., Tamburini, J., & Brice, P. (2018). Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. British Journal of Haematology, 181(3), 341–349. https://doi.org/10.1111/bjh.15184
Gauthier, J., Poiré, X., Gac, A.-C., Leclerc, M., Guillaume, T., Chalandon, Y., Nguyen, S., Forcade, E., Régny, C., Bay, J.-O., Bazarbachi, A., Rohrlich, P.-S., Huynh, A., Farhi, J., Marchand, T., Malfuson, J.-V., Pilorge, S., Labussière-Wallet, H., Renard, C., … Yakoub-Agha, I. (2018). Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 53(4), 400–409. https://doi.org/10.1038/s41409-017-0018-z
Ittel, A., Gervais, C., Galoisy, A. C., M’Kacher, R., Mauvieux, L., & Fornecker, L. M. (2017). Triradial and quadriradial chromosomes detected in a case of B-cell prolymphocytic leukaemia. British Journal of Haematology, 179(5), 704. https://doi.org/10.1111/bjh.14895
Alhosin, M., León-González, A. J., Dandache, I., Lelay, A., Rashid, S. K., Kevers, C., Pincemail, J., Fornecker, L.-M., Mauvieux, L., Herbrecht, R., & Schini-Kerth, V. B. (2015). Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2/Bad pathway. Scientific Reports, 5, 8996. https://doi.org/10.1038/srep08996
Miguet, L., Lennon, S., Baseggio, L., Traverse-Glehen, A., Berger, F., Perrusson, N., Chenard, M.-P., Galoisy, A.-C., Eischen, A., Mayeur-Rousse, C., Maar, A., Fornecker, L., Herbrecht, R., Felman, P., Van Dorsselaer, A., Carapito, C., Cianférani, S., & Mauvieux, L. (2013). Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. Leukemia, 27(8), 1748–1750. https://doi.org/10.1038/leu.2013.3
Miguet, L., Béchade, G., Fornecker, L., Zink, E., Felden, C., Gervais, C., Herbrecht, R., Van Dorsselaer, A., van Dorsselaer, A., Mauvieux, L., & Sanglier-Cianferani, S. (2009). Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. Journal of Proteome Research, 8(7), 3346–3354. https://doi.org/10.1021/pr801102c